1. Describe the immunologic barriers that limit effective immunotherapy in high-grade glioma
  2. Explain the mechanisms of action of oncolytic viruses, including direct oncolysis, immune priming, and modulation of the tumor microenvironment 
  3. Evaluate emerging clinical trial data assessing safety, efficacy, and immune correlates of oncolytic viral therapies in glioma patients.
  4. Discuss rational combination strategies integrating oncolytic viruses with other immunotherapy strategies
Session date: 
04/01/2026 - 8:00am to 9:00am CDT
Location: 
UT Southwestern Medical Center
Dallas, TX
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA
  • 1.00 Attendance
Please login or create an account to take this course.